Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor
positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed …

The estrogen receptor (ER) is an important driver in the proliferation, tumorigenesis, and
progression of breast cancers, and targeting ER signaling at different levels is a successful …

Drugs that inhibit estrogen receptor alpha (ERα) or that block the production of estrogens
remain frontline interventions in the treatment and management of breast cancer at all …

Estrogen receptor-positive (ER+) is the most common subtype of breast cancer. Endocrine
therapy is the fundamental treatment against this entity, by directly or indirectly modifying …

Anti-estrogen therapy is a key component of the treatment of both early and advanced-stage
hormone receptor (HR)-positive breast cancer. This review discusses the recent emergence …

Selective estrogen receptor downregulators (SERDs) are a novel class of compounds
capable of reducing the ERα protein level and blocking ER activity. Therefore, SERDs are …

Endocrine therapy (ET) is the cornerstone of management in hormone receptor (HR)+ breast
cancer (BC). Indeed, targeting the estrogen receptor (ER) signaling at different levels is a …

The identification of the estrogen receptor (ER) provided the first target for antiestrogenic
therapeutic agents. Endocrine therapies, either by blocking or downregulating the receptor …

The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary
gland development, breast carcinogenesis and the progression of breast tumours into lethal …

Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER
positive breast cancers. Selective modulation of ER has been a therapeutic target for this …